Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands

Rhea-AI Summary

Insulet has announced the full commercial launch of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) in the UK and the Netherlands. This system, compatible with Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitors, is available for individuals aged two and older with type 1 diabetes. Omnipod 5 is the first tubeless automated insulin delivery system integrated with both leading CGM sensor brands. It offers proactive glucose control, is waterproof, and aims to provide ease of use with demonstrated clinical results such as lower A1c levels and improved time in range. Patrick Crannell, Insulet's Senior VP, highlights the system's ability to allow users to choose their preferred CGM sensor, potentially benefiting thousands more people with diabetes.

Professor Partha S. Kar from NHS England emphasized the system's capacity to significantly simplify diabetes management. Clinical results have shown strong performance in maintaining glucose levels within the desired range while minimizing hypoglycemia instances.

Positive

• Full commercial launch of Omnipod 5 in the UK and the Netherlands.
• Compatible with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus CGM sensors.
• First tubeless automated insulin delivery system integrated with leading CGM brands.
• Strong clinical results: lower A1c and improved time in range.
• Proactive glucose control and waterproof design.
• Availability for individuals aged two years and older.

Negative

• None.

Financial Analyst

Insulet's full commercial launch of the Omnipod 5 in the U.K. and the Netherlands signifies a strategic expansion into new markets, which could pave the way for increased revenue streams. The integration with Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitors (CGMs) could attract a broader customer base due to the flexibility and convenience it offers. This move not only enhances the product's value proposition but also strengthens Insulet's competitive position in the diabetes management market.

The financial implications of this launch should be closely watched. If successful, it may lead to a significant uptick in sales, bolstering the company's top-line growth. Investors should keep an eye on subsequent quarterly reports to see if there is a corresponding rise in revenue. Additionally, market penetration in these regions will be crucial. If Insulet can achieve substantial market share, it can establish a strong foothold that may be difficult for competitors to dislodge.

Given the positive clinical outcomes associated with Omnipod 5, such as lower A1c levels and improved time in range, the product’s reception among healthcare providers and patients will be a key metric to monitor. Any positive feedback could drive further adoption and long-term revenue growth.

Medical Research Analyst

From a medical research perspective, the full commercial launch of Omnipod 5 with expanded sensor integrations represents a noteworthy advancement in diabetes care. The compatibility with two leading CGMs, Dexcom G6 and Abbott FreeStyle Libre 2 Plus, demonstrates a commitment to offering versatile and user-centric solutions. This kind of integration can significantly improve patient adherence to diabetes management regimens, as users are able to choose their preferred CGM without being locked into a single ecosystem.

The clinical data cited, including lower A1c levels and improved time in range for users, reinforces the system’s efficacy and potential to improve quality of life for individuals with type 1 diabetes. These outcomes are pivotal as they directly correlate with reduced long-term complications and healthcare costs for patients. Additionally, the ease of use and automation features of the Omnipod 5 can alleviate the daily burden of diabetes management, which is a critical factor for patient satisfaction and long-term use.

Overall, this launch could signify a paradigm shift in how diabetes is managed, offering more freedom and potentially better health outcomes for patients.

Following a successful limited market release, the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now fully available with Dexcom G6 and Abbott FreeStyle Libre 2 Plus in these countries

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod^® brand of products, today announced that Omnipod 5, compatible with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor (CGM) sensors, is now fully available in the U.K. and the Netherlands for individuals aged two years and older with type 1 diabetes. Omnipod 5 is the first and only tubeless automated insulin delivery (AID) system integrated with both of the leading CGM sensor brands, Dexcom and Abbott FreeStyle Libre.

“Expanding global access to Omnipod 5 is one of our top priorities. With the exciting, updated compatibility with both the Abbott FreeStyle Libre 2 Plus and the Dexcom G6 sensors, thousands more people with diabetes can enjoy the incredible freedom of tubeless, automated insulin delivery without having to change their CGM sensor brand. This is a game-changer for diabetes management,” said Patrick Crannell, Insulet Senior Vice President and International General Manager.

Omnipod 5 is the first tubeless, waterproof¹ AID system with proactive glucose control. The System is designed to be customer-centric and aims to deliver exceptional ease of use. It has demonstrated strong clinical results including lower A1c and improved time in range, while maintaining low time in hypoglycemia.^2,3

“Pod therapy is great because it is tubeless, and easy to use,” said Dion Screever, an 18-year-old student from the Netherlands. “When I started on Omnipod 5, I immediately noticed that my blood sugar was in range with much less effort from me, because of the automated insulin delivery technology. As someone who has lived with type 1 diabetes for nine years, Omnipod 5 has been life changing, giving me more freedom to live the way I want to.”

Multiple sensor integrations including Dexcom G6 and Abbott FreeStyle Libre 2 Plus give prescribers greater flexibility when recommending a sensor for their patients and make it simple to begin AID therapy with Omnipod 5. Customers can select the sensor they would like to connect to Omnipod 5 during the setup process.

Professor Partha S. Kar, Type 1 Diabetes and Technology Lead at NHS England and a consultant endocrinologist at Portsmouth Hospitals NHS Trust said, “The recent integration of Omnipod 5 with the FreeStyle Libre 2 Plus sensor will allow the life changing benefits of AID to be brought to many more people throughout the U.K., and also in the Netherlands. This is an exciting next step on this incredible journey to simplify life for people with type 1 diabetes.”

To learn more or to get started, visit the Omnipod website.

¹ The Pod has an IP28 rating for up to 7.6 meters (25 feet) for 60 minutes. The Omnipod^® 5 controller is not waterproof. The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under 2.4 meters (8 feet) of water for up to 24 hours without failure when properly installed. The FreeStyle Libre 2 Plus sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.

² Sherr JL, et al. Diabetes Care (2022). Study in 80 people with type 1 diabetes (T1D) aged 2 - 5.9 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.

³ Brown et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be fully controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.

©2024 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240620287127/en/

Investor Relations:

Deborah R. Gordon

Vice President, Investor Relations

(978) 600-7717

dgordon@insulet.com

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

awiczek@insulet.com

Source: Insulet Corporation

FAQ

What countries is the Omnipod 5 now available in?

The Omnipod 5 is now fully available in the UK and the Netherlands.

What are the compatible CGM sensors for Omnipod 5?

Omnipod 5 is compatible with Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitors.

What age group can use the Omnipod 5?

The Omnipod 5 can be used by individuals aged two years and older.

What are the clinical benefits of using Omnipod 5?

Clinical benefits include lower A1c levels, improved time in range, and reduced instances of hypoglycemia.

Who is the Senior Vice President speaking about Omnipod 5?

Patrick Crannell, Insulet Senior Vice President and International General Manager, spoke about Omnipod 5.

What is the stock symbol for Insulet ?

The stock symbol for Insulet is PODD.